Xconomy | Boston - Business + Technology in the Exponential Economy

GTC Drug Gets Orphan Status
Genzyme Arthritis Treament Approval Delayed
Indevus Puts New Acromegaly Treatment Head-to-Head with Novartis Treatment in Phase 3 Trial
GTC Biotherapeutics Drug Passes Clinical Milestone, Helping Blaze the Trail for U.S. “Pharming”
GTC Biotherapeutics, Racing Against Time to Prove the Worth of “Pharming”

Cancer Patient Can Use Newton Firm’s Drug, FDA Says

Pro-Pharmaceuticals of Newton, MA, announced today that it got the go-ahead from the FDA to treat one breast cancer patient with its lead drug candidate, Davanat. The drug, a carbohydrate polymer currently in Phase II trials for colorectal and biliary cancers, is designed to be used in combination with other cancer treatments.

Comments | Permalink |